A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
NCT07123038
This study is recruiting at 7 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Rheumatoid Arthritis (RA)
- Hidradenitis Suppurativa (HS)
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 71 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Sonoma Biotherapeutics, Inc.
- Last updated on ClinicalTrials.gov
- April 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- UCSF Medical Center · San Francisco, CA
- Stanford Medical Center · Stanford, CA
Colorado · 1
- University of Colorado · Aurora, CO
Illinois · 1
- Northwestern University · Chicago, IL
Massachusetts · 3
- Brigham and Women's Hospital · Boston, MA
- Massachusetts General Hospital · Boston, MA
- Tufts University · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.